The Life Sciences Report
Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Mining ReportMore Experts
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"NEO's Phase 2b PreSERVE AMI trial is well designed and well run." (6/4/14) NeoStem Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"OMER is a specialty pharma coupled with a true biotech company, and is working on a couple of exciting products." (6/4/14) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >
"I think that 2015 will be transformational, as KOOL gets ready to show us top-line data." (6/4/14) Cesca Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
Sector Experts
Jason Napodano
Jason Napodano currently works for Zacks Investment Research as the company's senior biotechnology analyst. In 2009, Napodano was promoted to managing director of research for Zacks' Small-Cap Research division, which focuses on writing high-quality institutional research on underfollowed or undervalued small-cap stocks. Prior to his tenure at Zacks, Napodano spent three years on the buyside with Eastover Capital in Charlotte, N.C., where he focused on large-cap equities and specialized in healthcare, energy and technology. Prior to joining Eastover, Napodano worked as a research scientist for TechLab Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases. He also spent a year working in a lab at the Fralin Biotechnology Center, and a year working for a cancer researcher in Virginia. Napodano has a bachelor's degree in biochemistry from Virginia Tech, with an additional bachelor's degree in chemistry and a minor in math. He has a master's degree in business administration and finance, with a concentration in securities analysis, from Wake Forest University. Napodano is also a Chartered Financial Analyst (CFA).
Recent Interviews
Off to the Races with Seven Extraordinary Biotech and Medtech Companies: Jason Napodano (8/1/13) Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors.
Zacks Analyst Jason Napodano's Six Biotech Picks Will Keep Your Profits on Solid Ground (12/13/12) Low valuation in biotech can be like quicksand under a mirage of low-hanging fruit. That's because the market is inhabited by growth investors who think cheap stocks are cheap for a reason. Zacks Investment Research Senior Biotechnology Analyst Jason Napodano operates with this in mind as he evaluates biotech companies. He also understands that while value can be a good friend, an investor's best buddy is momentum powered by vital market-moving events. Napodano shares his best stock ideas in this Life Sciences Report interview.
Recent Quotes
"We continue to be optimistic on the future of CUR." (6/25/14) Neuralstem Inc. - Jason Napodano, Zacks Small-Cap Research More >
"We believe CTH's APL-130277 is a potential $700M product." (5/29/14) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >
"We feel confident that BLU's Phase 3 trial for Kiacta will be successful." (5/20/14) BELLUS Health Inc. - Jason Napodano, Seeking Alpha More >
"CTH shares offer a potential sixfold increase in returns." (5/8/14) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research More >
"AMBS now has the financial resources to drive its assets forward." (4/25/14) Amarantus BioScience Holdings Inc. - Jason Napodano, Zacks Small-Cap Research More >
"NSI-566 in amyotrophic lateral sclerosis and spinal cord injury alone make CUR an attractive investment." (4/21/14) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >
"CTH has huge upside, a clear exit strategy and a drug that works." (4/16/14) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >
"CTH shares offer a potential sixfold increase in returns." (3/28/14) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research More >
"CUR continues on track with development of its lead compounds and has raised significant amounts of cash recently." (3/11/14) Neuralstem Inc. - Jason Napodano, Zacks Small-Cap Research More >
"AMBS will exercise outstanding warrants that will deliver +$3M." (2/18/14) Amarantus BioScience Holdings Inc. - Jason Napodano, Seeking Alpha More >
"There is a lot to be encouraged by from CUR's phase 1 trial data." (2/17/14) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >
"CTH is one of our best ideas in the small-cap biotechnology sector." (2/11/14) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >
"CUR is firing on all cylinders." (1/22/14) Neuralstem Inc. - Jason Napodano, Zacks Small-Cap Research More >
"We are hoping for U.S. full device clearance for DRIO's Dario by the end of 2014." (1/22/14) LabStyle Innovations Corp. - Jason Napodano, Zacks Small-Cap Research More >
"We think CTH shares will triple in value in 2014." (12/26/13) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >
"CUR has a number of catalysts on the near-term horizon that will drive the shares significantly higher." (12/26/13) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >
"CTH's concept is simple and the path to commercialization has been validated; we like the story." (11/26/13) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >
"We remain optimistic on DRIO's Dario application and device story." (11/20/13) LabStyle Innovations Corp. - Jason Napodano, Zacks Small-Cap Research More >
"We believe fundamentals are improving at AMBS." (11/19/13) Amarantus BioScience Holdings Inc. - Jason Napodano, Seeking Alpha More >
"AMBS announced positive analytical performance data for the LymPro test." (10/14/13) Amarantus BioScience Holdings Inc. - Jason Napodano, Zacks Small-Cap Research More >
"DRIO's shares are meaningfully undervalued in our view." (9/30/13) LabStyle Innovations Corp. - Jason Napodano, Zacks Small-Cap Research More >
"AVH is highly attractive for long-term investment in our view." (9/12/13) Avita Medical Ltd. - Jason Napodano, Zacks Small-Cap Research More >
"CTH's apomorphine offers significant upside with limited cash commitment." (8/23/13) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Investment Research More >
"CUR is well funded with several clinical catalysts on the horizon." (8/12/13) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >
"AVH's ReCell product is fantastic because all that is needed is skin from a donor site about the size of a postage stamp." (8/1/13) Avita Medical Ltd. - The Life Sciences Report Interview with Jason Napodano More >
"CTH is a very clean, low-risk story, and it's the first to patent this delivery." (8/1/13) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"If this NSI-189 molecule hits, it could be a tenbagger for CUR." (8/1/13) Neuralstem Inc. - The Life Sciences Report Interview with Jason Napodano More >
"DRIO's product has a truly elegant design." (8/1/13) LabStyle Innovations Corp. - The Life Sciences Report Interview with Jason Napodano More >
"CUR is an intriguing long-term investment." (6/19/13) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >
"We are initiating coverage of AVH with a Buy rating." (6/17/13) Avita Medical Ltd. - Jason Napodano, Zacks Small-Cap Research More >
"If ADXN finds a partner for dipraglurant, its shares could see double digits." (6/7/13) Addex Therapeutics - Jason Napodano, Zacks Small-Cap Research More >
"We see low clinical development risk of CTH's APL-130277." (6/5/13) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research More >
"We are initiating coverage of CTH with a Buy rating; we believe its focus on developing a sublingual form of the Parkinson's drug apomorphine offers significant upside potential." (6/3/13) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research More >
"DRIO has developed a leap forward for glucometers and diabetes management systems." (5/15/13) LabStyle Innovations Corp. - Jason Napodano, Zacks Investment Research More >
"ADXN's new strategy aims to reduce the time and cost of drug development while guaranteeing market exclusivity." (5/15/13) Addex Therapeutics - Jason Napodano, Zacks Small-Cap Research More >
"We continue to be optimistic on CUR; our rating is Outperform." (5/13/13) Neuralstem Inc. - Jason Napodano, Zacks Investment Research More >
"We believe CUR's dual-technology platform gives investors the best of both worlds." (3/15/13) Neuralstem Inc. - Jason Napodano, Zacks Small-Cap Research More >
"If CUR can develop a therapy for ALS, it would be sitting on a blockbuster." (12/13/12) Neuralstem Inc. - The Life Sciences Report Interview with Jason Napodano More >
Notable Quotes
"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >
"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >
"We believe BLU has a higher probability of success in its current Phase 3 Kiacta study." (6/12/14) BELLUS Health Inc. - The Life Sciences Report interview with Brian Bloom More >
"TRX is my favorite specialty pharmaceutical company right now, based on its valuation." (6/12/14) Tribute Pharmaceuticals Canada Inc. - The Life Sciences Report interview with Brian Bloom More >